



Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

October 2, 2024

MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2024 Cell & Gene Meeting on the Mesa being held October 7-9, 2024 at the Arizona Biltmore in Phoenix, AZ.

"The Cell & Gene Meeting on the Mesa convenes industry decision-makers to address all aspects of translating cutting-edge science into effective treatment options—especially where no treatment options exist," said Dr. Musunuri. "The Alliance for Regenerative Medicine is leading the way in support of advanced therapies and this gathering reflects the organization's impact in advocating for patients, healthcare systems, and society."

During his presentation, Dr. Musunuri will provide an overview of Ocugen's first-in-class modifier gene therapy platform, including the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa, OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy, and OCU410ST Phase 1/2 GARDian clinical trial for Stargardt disease. With dosing in the Phase 3 trial underway, OCU400 remains on track for its 2026 BLA and MAA approval targets.

In addition to Dr. Musunuri's session, members of Ocugen's executive team will conduct one-on-one meetings to showcase the Company's business and clinical development strategy.

Details of the presentation are as follows:

Date: Monday, October 7, 2024

Time: 1:30 p.m. MST

Location: Arizona Biltmore, FLW, Ballroom F

Virtual attendance is available, which includes a livestream of Ocugen's presentation and on-demand viewing of all conference sessions. Please visit <https://meetingonthemesa.com> for full information including registration.

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients' lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on [X](#) and [LinkedIn](#).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:

Tiffany Hamilton

Head of Communications

Tiffany.Hamilton@ocugen.com